Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18948719 | 0.90 | ZDHHC20 (0.39) | ZDHHC20ZDHHC2TSHR | |
| SCHEMBL20216191 | 0.87 | ZDHHC20 (0.32) | ZDHHC20ZDHHC2ALDH1A1TSHR | |
| SCHEMBL9004532 | 0.81 | THRA (0.32) | ZDHHC20ZDHHC2ALDH1A1TSHR | |
| SCHEMBL18897162 | 0.81 | ZDHHC20 (0.40) | ZDHHC20ZDHHC2 | |
| SCHEMBL308561 | 0.78 | — | — | |
| SCHEMBL21166401 | 0.78 | ZDHHC20 (0.38) | ZDHHC20ZDHHC2ALDH1A1 | |
| SCHEMBL19569740 | 0.77 | CASP1 (0.33) | ZDHHC20ZDHHC2 | |
| SCHEMBL18737520 | 0.77 | ZDHHC20 (0.37) | ZDHHC20ZDHHC2TSHR | |
| Trimethylammonium SCHEMBL170933 | 0.77 | ZDHHC20 (0.40) | ZDHHC20ZDHHC2ALDH1A1TSHR | |
| SCHEMBL3255350 | 0.76 | ALDH1A1 (0.38) | ZDHHC20ZDHHC2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ZDHHC20 958/4885ZDHHC2 905/4885ALDH1A1 684/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | ZDHHC20 2150/4885ZDHHC2 2325/4885ALDH1A1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.